VEEV:NYE-Veeva Systems Inc. Class A

EQUITY | Health Information Services | New York Stock Exchange

Last Closing

USD 174.33

Change

-0.76 (-0.43)%

Market Cap

USD 6.08B

Volume

0.66M

Analyst Target

USD 130.13
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Veeva Systems Inc is a provider of industry-specific, cloud-based software solutions for the life sciences industry.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-07-15 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
DOCS Doximity Inc

N/A

USD 5.21B
EVH Evolent Health Inc

+0.60 (+1.87%)

USD 3.72B
TDOC Teladoc Inc

+0.22 (+1.46%)

USD 2.53B
AGTI Agiliti Inc

-0.05 (-0.49%)

USD 1.38B
PHR Phreesia Inc

+0.69 (+2.91%)

USD 1.30B
NRC National Research Corp

-0.30 (-0.76%)

USD 0.95B
MPLN MultiPlan Corporation

+0.09 (+11.58%)

USD 0.48B
AMWL American Well Corp

+0.02 (+2.95%)

USD 0.25B
OWLT Owlet Inc

-0.19 (-4.25%)

USD 0.04B
FOXO FOXO Technologies Inc.

+0.02 (+5.11%)

USD 3.01M

ETFs Containing VEEV

EKG First Trust Nasdaq Lux Di.. 8.13 % 0.00 %

+0.30 (+0%)

USD 1.51M
CURE:XETRA VanEck Genomics and Healt.. 7.12 % 0.00 %

+0.14 (+0%)

USD 7.01M
FDHT 5.31 % 0.00 %

N/A

N/A
FDHT:XETRA Fidelity Digital Health U.. 5.11 % 0.00 %

+0.03 (+0%)

USD 4.86M
MOAT:SW VanEck Morningstar US Sus.. 2.61 % 0.00 %

+0.23 (+0%)

N/A
GOAT:AU VanEck Morningstar World .. 2.26 % 0.00 %

+0.15 (+0%)

USD 0.04B
WCLD WisdomTree Cloud Computin.. 1.56 % 0.00 %

+0.22 (+0%)

USD 0.65B
IHF iShares U.S. Healthcare P.. 0.00 % 0.43 %

+0.43 (+0%)

USD 0.87B
MOAT 0.00 % 0.49 %

N/A

N/A
QRH:CA 0.00 % 1.20 %

N/A

N/A
EASI 0.00 % 0.75 %

N/A

N/A
MOAT:LSE VanEck Morningstar US Sus.. 0.00 % 0.00 %

+0.10 (+0%)

USD 0.51B
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.00 %

+0.08 (+0%)

USD 0.02B
GMVM:XETRA VanEck Morningstar US Sus.. 0.00 % 0.00 %

+0.15 (+0%)

USD 0.51B
VMOM:XETRA 0.00 % 0.00 %

N/A

N/A
CLDL Direxion Daily Cloud Comp.. 0.00 % 0.00 %

-0.01 (0%)

USD 6.91M
LCG Sterling Capital Focus Eq.. 0.00 % 0.00 %

+0.15 (+0%)

USD 0.07B
WCLD:LSE WisdomTree Cloud Computin.. 0.00 % 0.00 %

-0.14 (0%)

USD 0.38B
MOGB:LSE VanEck Morningstar US Sus.. 0.00 % 0.00 %

+0.09 (+0%)

USD 0.51B
KLWD:LSE WisdomTree Cloud Computin.. 0.00 % 0.00 %

-11.00 (0%)

USD 0.34B

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 95.17% 100% F 99% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 95.17% 100% F 99% N/A
Trailing 12 Months  
Capital Gain 111.23% 100% F 99% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 111.23% 100% F 99% N/A
Trailing 5 Years  
Capital Gain 645.64% 100% F 99% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 645.64% 100% F 99% N/A
Average Annual (5 Year Horizon)  
Capital Gain 44.87% 88% B+ 87% B+
Dividend Return 44.87% 88% B+ 87% B+
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 34.69% 35% F 40% F
Risk Adjusted Return 129.33% 86% B+ 97% N/A
Market Capitalization 6.08B 100% F 92% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Health Information Services) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 109.90 100% 6%
Price/Book Ratio 19.20 25% 5%
Price / Cash Flow Ratio 0.00 25% 35%
Price/Free Cash Flow Ratio 0.00 25% 22%
Management Effectiveness  
Return on Equity 22.43% 100% 87%
Return on Invested Capital N/A N/A N/A
Return on Assets 10.10% 100% 93%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector